awmsg logo



5-aminolaevulinic acid (Ameluz®)


Reference No. 1074

Publication date:
03/12/2013


Last review date:
02/02/2017

Appraisal information

5-aminolaevulinic acid (Ameluz®) 78 mg/g gel


Company: Biofrontera
BNF category: Skin
NMG meeting date: 11/09/2013
AWMSG meeting date: 16/10/2013
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 2713
Ministerial ratification: 02/12/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

5-aminolaevulinic acid (Ameluz®) is recommended as an option for restricted use within NHS Wales for the treatment of actinic keratosis of mild to moderate severity on the face and scalp (Olsen grade 1 to 2) and of field cancerization in adults. 5-aminolaevulinic acid (Ameluz®) is recommended only when photodynamic therapy is considered appropriate.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download